[Clinical use of the Bretschneider HTK cardioplegic solution for in situ protection of the kidney].
The first clinical use of Bretschneider's HTK-solution for in-situ-protection of the kidney in mild hypothermia is reported. By means of this protective method renal surgery can be performed in a bloodless field without permanent loss of renal function. After initial protective perfusion of the kidney no repeated perfusions or additional surface cooling must be done. There are no systemic side effects when the HTK-solution is applied appropriately.
D002314:Cardioplegic Solutions; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D006391:Hemangioma / Q000601:surgery*; D006801:Humans; D007677:Kidney Function Tests; D007680:Kidney Neoplasms / Q000601:surgery*; D008067:Lipoma / Q000601:surgery*; D008353:Mannitol / Q000008:administration & dosage; D008875:Middle Aged; D010477:Perfusion; D011189:Potassium Chloride / Q000008:administration & dosage; D011343:Procaine / Q000008:administration & dosage
C039984:Bretschneider cardioplegic solution; D002314:Cardioplegic Solutions; D008353:Mannitol; D011343:Procaine; D011189:Potassium Chloride; D005947:Glucose
Klinische Anwendung der kardioplegischen Lösung HTK nach Bretschneider zur in-situ-Protektion der Niere.